Merck & Company has received FDA approval for the use of KEYTRUDA in the treatment of patients with locally advanced or metastatic carcinoma of the esophagus or gastroesophageal junction that is not amenable to surgical resection or definitive chemoradiotherapy combined with platinum and fluoropyrimidine-based chemotherapy.